Curator Dashboard

A development-stage diagnostics company whose mission is to curb the spread of hospital-acquired infections and anti-microbial resistance by developing a small-footprint, inexpensive, and automated diagnostic instrument that will quickly deliver patient-specific information on 50+ genetic markers. With their on-chip, high-multiplex approach, they expect to offer a higher-performing, lower-cost, and more versatile solution versus bacterial culture and competing approaches in development.

• Resource
• SciCrunch
• 13 years ago - by Anonymous

A biotechnology company that has developed technology for synthesizing custom microarrays, the FlexArrayer. Its is a desk-top sized instrument which allows the researcher to generate, in their own laboratory, either a custom oligonucleotide array in a single day or oligonucleotide pool in a few days. Recent developments in synthesis chemistry allows many modifications to be incorporated or for alternative chemistries to be considered., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

• Resource
• SciCrunch
• 13 years ago - by Anonymous

Commercial organization that discovers, validates & analyzes genomic biomarkers with a focus on body fluid samples. Take advantage of their proven expertise in biomarker signature development and speed up your biomarker studies.

• Resource
• SciCrunch
• 13 years ago - by Anonymous

An Antibody supplier

• Resource
• SciCrunch
• 14 years ago - by Anonymous

Commercial organization that produces products for biomarker research and development. Their goal is to help customers and collaborators to improve clinical decisions through the use of molecular biomarkers. Their tools bring new insights into disease processes, improve disease detection, and contribute to a better understanding of biology.

• Resource
• SciCrunch
• 13 years ago - by Anonymous

A service-provider company specialized in developing and managing scientific research projects. Its mission is to support research activities from the idea to the realization of project. ALTA assists in finding the proper strategy, building European Consortia and putting science in the most appropriate administrative and management framework.

• Resource
• SciCrunch
• 13 years ago - by Anonymous

A matchmaker portal for the pharmaceutical industry worldwide offering a directory and contact platform. This includes a database of ten thousands of profiles of companies offering pharma services as well as a selection of companies including niche providers delivering the service of interest. The platform is used to search for human medicinal products, veterinary medicinal products, cosmeceuticals, nutriceuticals, medical devices, and diagnostics. The company''s platform also enables users to post their service requests, service offers, and APIs/intermediates; and interact with other users. In addition, it offers advice and operational support services for outsourcing and inlicensing processes, such as strategic, scientific, and regulatory advice related to due diligence and decision making of research and development, sourcing, and M and A processes; conduct of third party GMP and pharmacovigilance audits; customized interim solutions; and qualified person functions for GMP and pharmacovigilance. The company also serves various sectors of the life science industry, such as contract manufacture, laboratory investigations and contractual testing, clinical research organizations and pre-clinical research organizations, consulting and legal counseling, logistics and distribution, education, marketing, IT, and investment and financing sectors; and small and medium enterprises/pharma, academic, public institutions, and freelancers. (Bloomberg Businessweek)

• Resource
• SciCrunch
• 13 years ago - by Anonymous

An independent owner-operated contract research organization providing clinical research services to the biopharmaceutical industry and life science organizations. If you are looking for data management, biostatistics and EDC solutions or plan to conduct a high quality phase I-IV or non-interventional study in and outside of Germany KOEHLER eClinical is your partner in study planning, conduct, evaluation and publication.

• Resource
• SciCrunch
• 13 years ago - by Anonymous

A high technology company that is a developer and supplier of photonic and laser systems for microelectronics manufacturers. They manufacture a variety of products for testing and repairing equipment, and particularly products designed for use by manufacturers of other high-tech products. These include laser trimming systems. (Adapted from Wikipedia)

• Resource
• SciCrunch
• 13 years ago - by Anonymous

A non-profit organization to support the research of the IRCCS San Raffaele Hospital with the aim of helping the development of science in the service of medicine. To make progress and achieve new successes, which may also be of benefit to future generations, the Fondazione Centro San Raffaele Hospital supports through participation in invitations to national and international research and fundraising activities to individuals and businesses. The lines of research in 2013 which focuses on the activities of the Foundation, in synergy with the San Raffaele hospital: # Molecular and functional approaches to the study of neurological and psychiatric disorders # Molecular and cellular therapies for regenerative medicine # Study and modulation of innate and adaptive immune response # Cellular and molecular approaches to the study of solid tumors and blood # Molecular and cellular approaches to the study and treatment of cardiovascular and metabolic diseases # Genetic mechanisms, molecular and cellular disease and aging # Genomics and post-genomics for the study of the mechanisms of disease and response to drugs # Molecular and cellular imaging for the study of oncological diseases and molecular imaging of cardiovascular disease

• Resource
• SciCrunch
• 13 years ago - by Anonymous

A website where users can find information on donating tissue for ataxia research.

• Resource
• SciCrunch
• 15 years ago - by Anonymous

A set of three models, which in conjunction with the semantic mediator enables the execution of queries formulated through the eligibility representation of the Clinical research information model (WT6.4). An ontology-driven mechanism was developed to enable linkage and integration of phenotypic and genotypic data from multiple distributed data sources. It makes use of the Clinical Data Integration Model (CDIM, WT6.5), the Data Source Model (DSM, WT6.6) and the CDIM-DSM mapping model (WT6.6). Queries formulated through the CDIM and vocabulary service (WT7.2) are translated to local queries by the mediator using the individual source instances of the DSM and CDIM-DSM models.

• Resource
• SciCrunch
• 13 years ago - by Anonymous

A structured controlled vocabulary of stage-specific anatomical structures of the mouse (Mus).

• Resource
• SciCrunch
• 13 years ago - by Anonymous

Charity registered in United Kingdom whose mission is to accelerate research in new areas of human biology and drug discovery.Not for profit, public-private partnership that carries out basic science of relevance to drug discovery whose core mandate is to determine 3D structures on large scale and cost effectively targeting human proteins of biomedical importance and proteins from human parasites that represent potential drug targets.

• Resource
• SciCrunch
• 13 years ago - by Anonymous

A clinical research information model for the integration of clinical research covering randomized clinical trials (RCT), case-control studies and database searches into the TRANSFoRm application development. TRANSFoRm clinical research is based on primary care data, clinical data and genetic data stored in databases and electronic health records and employs the principle of reusing primary care data, adapting data collection by patient reported outcomes (PRO) and eSource based Case Report Forms. CRIM was developed using the TRANSFoRm clinical use cases of GORD and Diabetes. Their use case driven approach consisted of three levels of modelling drawing heavily on the clinical research workflow of the use cases. Different available information models were evaluated for their usefulness to represent TRANSFoRm clinical research, including for example CTOM of caBIG, Primary Care Research Object Model (PRCOM) of ePCRN and BRIDG of CDISC. The PCROM model turned out to be the most suitable and it was possible to extend and modify this model with only 12 new information objects, 3 episode of care related objects and 2 areas to satisfy all requirements of the TRANSFoRm research use cases. Now the information model covers Good Clinical Practice (GCP) compliant research, as well as case control studies and database search studies, including the interaction between patient and GP (family doctor) during patient consultation, appointment, screening, patient recruitment and adverse event reporting.

• Resource
• SciCrunch
• 13 years ago - by Anonymous

Project to develop a ''rapid learning healthcare system'' driven by advanced computational infrastructure that can improve both patient safety and the conduct and volume of clinical research in Europe. Three carefully chosen clinical ''use cases'' will drive, evaluate and validate the approach to the ICT (information and communications technology) challenges. The project will build on existing work at international level in clinical trial information models (BRIDG and PCROM), service-based approaches to semantic interoperability and data standards (ISO11179 and controlled vocabulary), data discovery, machine learning and electronic health records based on open standards (openEHR). TRANSFoRm will extend this work to interact with individual eHR systems as well as operate within the consultation itself providing both diagnostic support and support for the identification and follow up of subjects for research. The approach to system design will be modular and standards-based, providing services via a distributed architecture, and will be tightly linked with the user community. Four years of development and testing will end with a fifth year that will be dedicated to summative validation of the project deliverables in the Primary Care setting. In order to support patient safety in both clinical and research settings, significant ICT challenges need to be overcome in the areas of interoperability, common standards for data integration, data presentation, recording, scalability, and security., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

• Resource
• SciCrunch
• 13 years ago - by Anonymous

• Organization
• SciCrunch
• 18 years ago - submitted by Eddy Kim

Consortium aiming to produce regulatory T cells that are compatible with a kidney transplant patient''''s immune system, as a measure to suppress the body''''s natural immune response against a transplanted organ. If successful, this approach will reduce a transplantation patient''''s life-long dependency on immune suppressing drugs, many of which are often associated with undesirable side effects and can limit the patient''''s daily routine. The consortium goals are to develop and conduct clinical trials of various immunoregulatory T-cell-based products in organ transplantation recipients, allowing a direct comparison of the safety, clinical practicality and therapeutic efficacy of each cell type. The central focus of the project is to: # Production and manufacture of distinct populations of hematopoietic immunoregulatory T cells # Comparatively study the tolerogenic characteristics of these regulatory cell types # Test these cell therapy products side by side in a clinical trial living donor renal transplant recipients The first workstream will work with different T regulatory cell, tolerogenic DC and suppressive macrophage cell products that are currently in development. In addition to these therapeutics, another goal of this workstream is to develop a cell tracking technology that assesses pharmacodynamics and pharmacokinetics of these cell-based therapies. The second workstream is focused on designing and conducting a cell therapy based clinical trial in renal transplantation, taking into consideration ethics, concurrent immunosuppressive drug use, state-of-the-art immune monitoring, innovative all-in-one data capturing systems, and pharmacovigilance. The goal is to have a comparative evaluation of hematopoietic cell therapy safety in renal transplantation. The third workstream aims to learn more about the specific comparative characteristics of suppressive cell types and to use this knowledge to improve later trial designs and foster novel ideas for new or improved suppressive / tolerogenic cell population.

• Organization
• Consortia-pedia, a FasterCures Project
• 13 years ago - by Anonymous

A global mediation model expressed as an ontology for use in the primary care domain. It uses a realist approach employing Basic Formal Ontology (BFO v1.1) as an upper ontology. Other ontologies were imported or specialized to give deeper definition to the concepts in the domain. These included OGMS, IAO and VSO. The CDIM ontology includes concepts that are especially important to primary care (e.g. episode of care or reason for encounter), but also others to handle temporality in queries (e.g. the start and beginning of processes). The owl file provided for download is the merged file created directly in Prot��g�� through the Refactor/Merge ontologies tool in order to facilitate the load of CDIM in LexEVS for use in the unified interoperability framework.

• Resource
• SciCrunch
• 13 years ago - by Anonymous

Consortium to accelerate new breakthrough DNA sequencing technologies and methods to enhance existing analysis methods. The ultimate aim is to advance DNA sequencing technologies to a level where a human genome can be analyzed at high resolution for less than 1000 euros in less than one day. The goals of the consortium are to revolutionize nucleic acid analysis methods by improving elements necessary to use the currently emerging generation of nucleic acid sequencers in a meaningful and accessible way, providing methods that allow in situ nucleic acid analysis and methods capable of selectively characterizing mutant DNA in a high background of wildtype DNA, combining RNA and DNA analysis in a single analytical device, providing technology to efficiently analyze DNA methylation (genome-wide, with high resolution and in its long-range context), implementing novel concepts for high-throughput HLA-screening, developing fully integrated solutions for mutational screening of small target regions (such as for screening newborns for cystic fibrosis mutations), developing a device for screening multiple target regions with high accuracy and implementing strategies for effective and high-resolution genotyping of copy number variations. READNA was awarded the Stars of Europe prize in December 2013.

• Organization
• Consortia-pedia, a FasterCures Project
• 13 years ago - by Anonymous